Payment overview · 2025
General Payments
$2,163.25
45 reported records · 15 companies
Healthcare provider profile · identity verified
Ritesh Gupta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MOBILE, AL · NPI 1124100847
Verified facts
What the public records show
CMS Open Payments records show Ritesh Gupta, MD received $2,163.25 in general payments during 2025 across 45 reported records.
Medtronic, Inc. accounted for 64.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,389.81 | 64.2% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $196.32 | 9.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $98.70 | 4.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.67 | 3.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $73.11 | 3.4% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $64.57 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.96 | 2.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.11 | 2.3% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $35.02 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.91 | 1.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.17 | 1.3% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.53 | 0.9% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $16.96 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.21 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,171.21 | 6 |
| Food and Beverage | $992.04 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $1,218.27 | 8 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $171.54 | 4 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $106.47 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $98.70 | 6 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $89.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $73.11 | 5 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $64.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.96 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $35.02 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 339 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
339 | 85 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
482 | 110 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1533 | 483 |
| Amlodipine Besylate | Amlodipine Besylate | 1220 | 418 |
| Carvedilol | Carvedilol | 1040 | 328 |
| Clopidogrel | Clopidogrel Bisulfate | 940 | 286 |
| Xarelto | Rivaroxaban | 811 | 188 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 772 | 253 |
| Pantoprazole Sodium | Pantoprazole Sodium | 705 | 259 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 678 | 231 |
| Potassium Chloride | Potassium Chloride | 558 | 199 |
| Furosemide | Furosemide | 523 | 202 |
| Entresto | Sacubitril/Valsartan | 482 | 110 |
| Ezetimibe | Ezetimibe | 452 | 145 |
| Losartan Potassium | Losartan Potassium | 430 | 152 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 423 | 141 |
| Eliquis | Apixaban | 339 | 85 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 326 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 100 |
| Lisinopril | Lisinopril | 239 | 81 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 222 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 199 | 82 |
| Repatha Sureclick | Evolocumab | 185 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 46 |
| Famotidine | Famotidine | 162 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 157 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 150 | 43 |
| Torsemide | Torsemide | 147 | 56 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 145 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 54 |
| Farxiga | Dapagliflozin Propanediol | 135 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 135 | 36 |
| Omeprazole | Omeprazole | 131 | 44 |
| Nitroglycerin | Nitroglycerin | 125 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 125 | 41 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 124 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 37 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 112 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 36 |
| Spironolactone | Spironolactone | 102 | 40 |
| Ranolazine Er | Ranolazine | 95 | 30 |
| Warfarin Sodium | Warfarin Sodium | 95 | 32 |
| Valsartan | Valsartan | 84 | 27 |
| Midodrine Hcl | Midodrine Hcl | 80 | 30 |
| Terazosin Hcl | Terazosin Hcl | 80 | 29 |
| Atenolol | Atenolol | 68 | 22 |
| Bupropion Xl | Bupropion Hcl | 68 | 22 |
| Sertraline Hcl | Sertraline Hcl | 66 | 21 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 22 |
| Simvastatin | Simvastatin | 57 | 18 |
| Ozempic | Semaglutide | 56 | 12 |
| Jardiance | Empagliflozin | 55 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 52 | 13 |
| Irbesartan | Irbesartan | 52 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 48 | 14 |
| Sotalol | Sotalol Hcl | 48 | 12 |
| Flecainide Acetate | Flecainide Acetate | 47 | 16 |
| Nifedipine Er | Nifedipine | 46 | 19 |
| Prasugrel Hcl | Prasugrel Hcl | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 42 | 21 |
| Metformin Hcl | Metformin Hcl | 42 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 38 | 19 |
| Ramipril | Ramipril | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Telmisartan | Telmisartan | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 35 | 12 |
| Edarbi | Azilsartan Medoxomil | 35 | suppressed |
| Prednisone | Prednisone | 34 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 14 |
| Brilinta | Ticagrelor | 32 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | 12 |
| Verapamil Er | Verapamil Hcl | 32 | 11 |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Alprazolam | Alprazolam | 21 | 21 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | 13 |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | 11 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Diazepam | Diazepam | 12 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,163.25 · 45 records | Medtronic, Inc. | AREXVY, Ambulatory Monitoring & Diagnostics Undivided, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CLOTTRIEVER BOLD CATHETER, ELIQUIS, FUROSCIX, JARDIANCE, JOT DX, Kerendia, LEQVIO, MITRACLIP, Ozempic, REPATHA, Rybelsus, SHINGRIX, SYMPLICITY G3, VENASEAL, VERQUVO, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error